

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA


ROCHESTER DRUG CO-OPERATIVE, INC.,	:	
on behalf of itself and all others similarly	:	
situated,	:	
Plaintiff	:	
	:	
v.	:	CIVIL ACTION NO. 16-6672
	:	
ACTAVIS ELIZABETH, LLC., <i>et al.</i> ,	:	
Defendants.	:	

ORDER

AND NOW, this 7th day of February 2017, upon consideration of the attached
Stipulation to Set Deadlines for Responsive Pleadings, it is hereby **ORDERED** that the
Stipulation is **APPROVED**.

It is so **ORDERED**.

BY THE COURT:


CYNTHIA M. RUFÉ, J.

02/07/2017 10:47 Doxycycline(A)

(FAX)

P.003/008

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

ROCHESTER DRUG CO-OPERATIVE,
INC., on behalf of itself and all others similarly
situated,

Plaintiff,

v.

ACTAVIS ELIZABETH, LLC, TEVA
PHARMACEUTICALS USA, INC., PLIVA,
INC., IMPAX LABORATORIES, INC.,
MYLAN, INC., MYLAN
PHARMACEUTICALS, INC., UDL
LABORATORIES, INC., ENDO
INTERNATIONAL PLC, PAR
PHARMACEUTICAL HOLDINGS, INC.,
HERITAGE PHARMACEUTICALS, INC.,
BRECKENRIDGE PHARMACEUTICALS,
INC., and UPSHER-SMITH
LABORATORIES, INC.,

Defendants.

Civil Action No. 2:16-cv-06672

The Honorable Cynthia M. Rufe

**JOINT STIPULATION AND [PROPOSED ORDER] TO SET DEADLINES FOR
RESPONSIVE PLEADINGS**

WHEREAS, Plaintiff Rochester Drug Co-operative, Inc. ("Plaintiff") has filed a putative class action complaint in this District alleging price fixing with respect to Propranolol against Defendants Actavis Elizabeth, LLC, Teva Pharmaceuticals USA, Inc., Pliva, Inc., Impax Laboratories, Inc., Mylan, Inc., Mylan Pharmaceuticals, Inc., UDL Laboratories, Inc., Endo International PLC, Par Pharmaceutical Holdings, Inc., Heritage Pharmaceuticals, Inc.,

02/07/2017 10:47 Doxycycline(A)

(FAX)

P.004/008

Breckenridge Pharmaceuticals, Inc.¹, and Upsher-Smith Laboratories, Inc. (“Defendants,” and together collectively with Plaintiff, the “Parties”).

WHEREAS, on January 5, 2017, Plaintiff filed a motion with the Judicial Panel on Multidistrict Litigation (“JPML”) for Transfer of Related Actions to the Eastern District of Pennsylvania for Coordinated or Consolidated Pretrial Proceedings as Part of MDL No. 2724 Pursuant to 28 U.S.C. § 1407 (the “Plaintiff’s MDL Motion”);

WHEREAS, responses to the Plaintiff’s MDL Motion were filed on January 30, 2017, and the JPML has not yet set the Motion for hearing;

WHEREAS, to economize both judicial and Parties’ resources pending the JPML’s decision on the Motion, the Parties believe and agree that Defendants’ time to move to dismiss, answer, or otherwise respond to Plaintiff’s complaint in this action should be extended until after the JPML has ruled on the pending Motion, it has been determined which court will preside over: the above-captioned Action, *FWK Holdings, LLC v. Actavis Elizabeth, LLC, et al*, 16-9901 (S.D.N.Y.), *Cesar Castillo v. Actavis Elizabeth, LLC, et al*, 17-0078 (S.D.N.Y.), and *Plumbers & Pipefitters Local 178 Health & Welfare Trust Fund v. Actavis Holdco U.S., Inc., et al*, 17-cv-0144 (E.D. Pa.), or any subsequently-filed antitrust putative class action concerning the pricing of Propranolol (collectively, the “Propranolol Actions”), and any consolidated amended complaint has been filed;

NOW, THEREFORE, pursuant to Local Rule 7.4, the parties hereby stipulate, and the Court orders, as follows:

1. Defendants’ time to answer, move or otherwise respond to Plaintiff’s complaint shall be extended until after disposition of the JPML proceeding, as provided below:

¹ The correct corporate name for this entity is Breckenridge Pharmaceutical, Inc.

- a. If the JPML transfers all the Propranolol Actions to a single district for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407, unless otherwise provided by the transferee court, Defendants shall, as permitted by Federal Rule 12, answer, move or otherwise plead in response to the complaint within 45 days after either: (i) the plaintiffs in the consolidated or coordinated actions serve a Consolidated or Amended Class Action Complaint, or (ii) the plaintiffs in the consolidated or coordinated actions serve written notice that they will not file a consolidated or amended complaint.
 - b. If the JPML denies the motions to transfer these cases and all related civil actions to a single district for coordinated or consolidated pretrial proceedings, Defendants shall, as permitted by Federal Rule 12, answer, move or otherwise plead in response to Plaintiff's complaint within 45 days of the later of (i) service of the JPML ruling; (ii) a decision on any motion pursuant to 28 U.S.C. §1404 that may be filed; or (iii) service of a Consolidated or Amended Class Action Complaint to which Plaintiff is a party.
2. Plaintiff shall have 45 days from the filing and service of any motions to dismiss to file and serve any memoranda in opposition thereto. Any reply memoranda shall be filed 30 days after service and filing of any opposition memoranda. If a filing deadline falls on a weekend or federal holiday, the memorandum shall be filed on the first business day following such weekend or holiday. No extension among Plaintiff and Defendants has been previously requested or granted by the Court. Defendants reserve the right to file a motion to sever parties, claims, or allegations in response to the complaint or at any time during the litigation.

3. Prior to the filing of any motion to dismiss by Defendants, Plaintiff and Defendants shall meet and confer regarding appropriate page limitations for memoranda in support of and in opposition to such motions, and for any replies, and submit to the Court a proposed order and stipulation regarding page limitations, or if the Parties cannot agree on page limitations, a proposed order identifying the differing proposals and a brief explanation by Plaintiff and Defendants, as a group, of the reasons therefor. Defendants will make good faith efforts to coordinate and consolidate common legal arguments, but reserve the right to file individual briefs to allow for Defendant specific arguments.

4. Defendants, other than Endo International plc, agree either that they have been properly served with process in this action or that they waive service of process under Rule 4(d) of the Federal Rules of Civil Procedure. Defendants otherwise expressly reserve the right to challenge the complaint and any Consolidated or Amended Class Action Complaint, on any and all other grounds, including personal jurisdiction.

IT IS SO STIPULATED AND ORDERED.

Dated: February 7, 2017

By: /s/ Dianne M. Nast
 Dianne M. Nast
 Erin C. Burns
 NASTLAW LLC
 1101 Market Street, Suite 2801
 Philadelphia, PA, 19107
 Tel. (215) 923-9300
 Fax. (215) 923-9302
 dnast@nastlaw.com
 eburns@nastlaw.com

David F. Sorensen
 Zachary D. Caplan
 BERGER & MONTAGUE, P.C.
 1622 Locust Street
 Philadelphia, PA 19103

By: /s/ Jan P. Levin
 Jan P. Levine
 Pepper Hamilton LLP
 3000 Two Logan Square
 Eighteenth & Arch Streets
 Philadelphia, PA 19103-2799
 Tel: (215) 981-4000
 Fax: (215) 981-4750
 levinej@pepperlaw.com

By: /s/ Sheron Korpus
 Sheron Korpus (*pro hac vice motion pending*)
 Kasowitz Benson Torres & Friedman LLP
 1633 Broadway
 New York, New York 10019
 Tel: (212) 506-1700

02/07/2017 10:48 Doxycycline(A)

(FAX)

P.007/008

Tel. (215) 875-3000
 Fax. (215) 875-4604
 dsorensen@bm.net
 zcaplan@bm.net

Peter Kohn
 Joseph T. Lukens
 FARUQI & FARUQI, LLP
 101 Greenwood Avenue
 Suite 600
 Jenkintown, PA 19046
 Tel. (215) 277-5770
 Fax. (215) 277-5771
 pkohn@faruqilaw.com
 jlukens@faruqilaw.com

Barry S. Taus
 Kevin Landau
 Archana Tamoshunas
 TAUS, CEBULASH & LANDAU, LLP
 80 Maiden Lane
 Suite 1204
 New York, NY 10038
 Tel. (212) 931-0704
 btaus@tcllaw.com
 klandau@tcllaw.com
 atamoshunas@tcllaw.com

Counsel for Rochester Drug Co-Operative, Inc. and the Proposed Direct Purchaser Class

Fax: (212) 506-1800
 skorpus@kasowitz.com

Counsel for Actavis Elizabeth, LLC, Teva Pharmaceuticals USA, Inc., and Pliva Inc.

By: /s Stacey Anne Mahoney
 Stacey Anne Mahoney
 Morgan, Lewis & Bockius LLP
 101 Park Avenue
 New York, NY 10178
 Telephone: (212) 309-6930
 Facsimile: (212) 309-6001
 stacey.mahoney@morganlewis.com

Counsel for Breckenridge Pharmaceutical, Inc.

By: /s D. Jarrett Arp
 D. Jarrett Arp (*pro hac vice motion pending*)
 Gibson, Dunn & Crutcher, LLP
 1050 Connecticut Avenue, N.W.
 Washington, DC 20036
 202-955-8678
 jarp@gibsondunn.com

Counsel for Heritage Pharmaceuticals Inc.

By: /s Chul Pak
 Chul Pak
 Wilson Sonsini Goodrich & Rosati
 Professional Corporation
 1301 Avenue of the Americas, 40th Fl.
 New York, NY 10019
 212-497-7726
 cpak@wsgr.com

Counsel for Mylan Inc., Mylan Pharmaceuticals Inc., and UDL Laboratories Inc.

By: /s Edward D. Hassi
 Edward D. Hassi
 O'Melveny & Meyers LLP
 1625 EYE Street, N.W.
 Washington, DC 20006

02/07/2017 10:48 Doxycycline(A)

(FAX)

P.008/008

202-383-5336
ehassi@omm.com

Counsel for Par Pharmaceutical, Inc.

By: /s Jay P. Lefkowitz, P.C.
Jay P. Lefkowitz, P.C.
Kirkland & Ellis LLP
601 Lexington Avenue
New York, NY 10022
212-446-4970
lefkowitz@kirkland.com

Counsel for Upsher-Smith Laboratories, Inc.

By: /s Raymond A. Jacobsen, Jr.
Raymond A. Jacobsen, Jr.
McDermott Will & Emery LLP
500 North Capitol Street, N.W.
Washington, DC 20001
202-756-8028
rayjacobsen@mwe.com

Nicole L. Castle
McDermott Will & Emery LLP
340 Madison Avenue
New York, NY 10173
Tel.: (212) 547-5480
Fax: (212) 547-5444
ncastle@mwe.com

*Counsel for Defendant Impax
Laboratories, Inc.*

APPROVED BY THE COURT:


The Honorable Cynthia M. Rufe